Business, energy, technology, markets and global industry news from Business News Today

Kesimpta

PharmaDeviceNews Kesimpta
Novartis is advancing oral BTK inhibitor remibrutinib toward global regulatory submissions after two successful Phase 3 multiple sclerosis trials. Representative image.
Pharma & Biotech

Can TG Therapeutics establish BRIUMVI superiority without a head-to-head clinical trial?

A peer-reviewed five-year indirect comparison associates BRIUMVI with lower modeled disability progression risk than ocrelizumab and ofatumumab. The findings support TG Therapeutics' commercial evidence strategy but cannot establish head-to-head superiority.

Read More
Novartis is advancing oral BTK inhibitor remibrutinib toward global regulatory submissions after two successful Phase 3 multiple sclerosis trials. Representative image.
Pharma & Biotech

Novartis’ remibrutinib wins two Phase 3 multiple sclerosis trials as BTK strategy gets a crucial lift

Remibrutinib beat teriflunomide on relapse rates and every key secondary endpoint across the Phase 3 REMODEL studies, while avoiding the liver-safety signal that has complicated development of other BTK inhibitors.

Read More